Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Private Equity-Backed Crealta Makes Its First Move With Savient Deal

This article was originally published in The Pink Sheet Daily

Executive Summary

A startup called Crealta Pharmaceuticals will acquire most of Savient’s assets, including the marketed gout drug Krystexxa, for $120.4 million following a bankruptcy court auction.

You may also be interested in...



Start-Up Quarterly Statistics, Q4 2013

Life science start-ups raised $1.18 billion in the final quarter of 2013, more than twice the $559.4 million they garnered in the previous quarter, and the most lucrative quarter reported for the group in the history of this START-UP column.

Regeneron Likely Facing New Gout Study Following Arcalyst “Complete Response” Letter

FDA’s decision not to approve rilonacept for preventing gout flares was unsurprising, given its Arthritis Advisory Committee’s unanimous recommendation against the indication. Regeneron says FDA’s letter requests “additional clinical data,” as well as chemistry, manufacturing and controls information.

Savient's New CEO Johnson Tasked With Turning Krystexxa Into A Commercial Success

Eli Lilly's oncology head John Johnson has been named to the top post at Savient Pharmaceuticals as the company tries to rebound from a failed sales attempt.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS075149

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel